Cancer Research

Combining Viruses and CAR-T Therapy to Fight B-Cell Cancers
Research & Development Combining Viruses and CAR-T Therapy to Fight B-Cell Cancers

By inducing the lysis of malignant cells, oncolytic viruses release a broad spectrum of neoantigens that can prime a patient’s native immune system through a process called epitope spreading. This mechanism represents a significant shift from the current clinical standard of single-target Chimeric

Challenges and Opportunities for Personalized mRNA Cancer Vaccines
Tech & Innovation Challenges and Opportunities for Personalized mRNA Cancer Vaccines

The current pharmaceutical landscape is witnessing a profound transformation as the successful clinical implementation of personalized mRNA cancer vaccines begins to redefine the standard of care in oncology. This seismic shift is driven by a long-held vision: the ability to train a patient’s own

What Is the Next Frontier in Oncology Innovation?
Research & Development What Is the Next Frontier in Oncology Innovation?

The oncology sector is shifting its primary focus from simply managing terminal disease to achieving functional cures that allow patients to live long, healthy lives. This transition marks a departure from the historical reliance on broad-spectrum treatments that often came with debilitating side

FDA Approves Guardant360 CDx for Serial Breast Cancer Care
Research & Development FDA Approves Guardant360 CDx for Serial Breast Cancer Care

The approval of Guardant360 CDx as a companion diagnostic for AstraZeneca’s camizestrant marks the first time a liquid biopsy has been authorized for continuous monitoring of cancer evolution. This regulatory milestone fundamentally alters the management of advanced breast cancer by allowing

Can Durvalumab Improve Gastric Cancer Survival Rates?
Research & Development Can Durvalumab Improve Gastric Cancer Survival Rates?

While immunotherapy was previously confined to treating advanced stages of the disease, new evidence shows its efficacy in earlier, resectable settings. Gastric cancer has long remained a formidable opponent within the global oncology landscape, currently ranking as the fifth most common cancer

What Is the Future of Synthetic CAR T-Cell Therapies?
Research & Development What Is the Future of Synthetic CAR T-Cell Therapies?

The inherent inefficiencies of the autologous model are tied to a one-batch-per-patient approach that restricts throughput and maintains high market prices for oncology treatments. While Chimeric Antigen Receptor (CAR) T-cell therapies have redefined oncology by providing life-saving results for

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later